260 related articles for article (PubMed ID: 33922052)
1. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
Front Immunol; 2021; 12():674400. PubMed ID: 34084172
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
6. Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
Quixabeira DCA; Jirovec E; Pakola S; Havunen R; Basnet S; Santos JM; Kudling TV; Clubb JHA; Haybout L; Arias V; Grönberg-Vähä-Koskela S; Cervera-Carrascon V; Pasanen A; Anttila M; Tapper J; Kanerva A; Hemminki A
Cancer Gene Ther; 2023 Nov; 30(11):1543-1553. PubMed ID: 37666898
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
8. Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.
Zafar S; Quixabeira DCA; Kudling TV; Cervera-Carrascon V; Santos JM; Grönberg-Vähä-Koskela S; Zhao F; Aronen P; Heiniö C; Havunen R; Sorsa S; Kanerva A; Hemminki A
Cancer Gene Ther; 2021 May; 28(5):442-454. PubMed ID: 32920593
[TBL] [Abstract][Full Text] [Related]
9. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
12. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
13. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
Cervera-Carrascon V; Quixabeira DCA; Havunen R; Santos JM; Kutvonen E; Clubb JHA; Siurala M; Heiniö C; Zafar S; Koivula T; Lumen D; Vaha M; Garcia-Horsman A; Airaksinen AJ; Sorsa S; Anttila M; Hukkanen V; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2020 Jun; 17():47-60. PubMed ID: 32322662
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
17. Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
Kudling TV; Clubb JHA; Quixabeira DCA; Santos JM; Havunen R; Kononov A; Heiniö C; Cervera-Carrascon V; Pakola S; Basnet S; Grönberg-Vähä-Koskela S; Arias V; Gladwyn-Ng I; Aro K; Bäck L; Räsänen J; Ilonen I; Borenius K; Räsänen M; Hemminki O; Rannikko A; Kanerva A; Tapper J; Hemminki A
Oncoimmunology; 2022; 11(1):2096572. PubMed ID: 35845722
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
19. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V
Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
